Nvidia posted record $68.1 billion Q4 revenue and $43B net income, driven by data center AI demand, and guided $78B revenue ...

Novo Nordisk (NVO) is upgraded to 'Hold' as its market cap returns to pre-GLP-1 mania levels, limiting further downside. NVO ...

When you click on “Accept all”, you consent to ads on this site being customized to a personal profile we or our advertising partners may have about you. Choose “Customize or Reject all” if you want ...

Hey folks, Pop Mart's Labubu exploded in 2025 with global sales topping 100 million units, helping drive total IP sales past ...

The popularity of the medication is boosting sales in hair and beauty products at the pharmacies giant, and a new oral version will drive demand even higher.

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Dayno emphasized, “Guiding WAKIX to blockbuster status in 2026, extending the WAKIX franchise with pitolisant GR's target PDUFA date in Q1 2027, expanding the pitolisant franchise with the advancement ...

The failure of its next-generation obesity drug to match Eli Lilly's blockbuster has blown a hole in Novo's post-Ozempic ...

Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and Rybelsus, by up to 50 percent beginning next year. Starting on Jan. 1, ...

The leadership imbalance is visible in B.C. Jeanne-Marie Owens, co-founder and COO of Vancouver-based Critical Path Games Ltd ...

The winners will not be those who merely predict cliffs, but those who re-architect early enough. Merck’s oncology spin-out underscores a defining reality of modern pharma: molecules may create value, ...

Vice President, Investor Relations at Ascendis Pharma A/S. Joining me on the call today are Jan Moller Mikkelsen, President ...